Genfit S.A. (NASDAQ:GNFT) Short Interest Down 40.5% in February

Genfit S.A. (NASDAQ:GNFT) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 60,300 shares, a decrease of 40.5% from the January 31st total of 101,300 shares. Based on an average trading volume of 8,400 shares, the short-interest ratio is currently 7.2 days. Currently, 0.1% of the shares of the stock are sold short.

Hedge Funds Weigh In On Genfit

A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC acquired a new position in shares of Genfit S.A. (NASDAQ:GNFT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned approximately 0.33% of Genfit at the end of the most recent quarter. 2.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Genfit in a report on Friday, February 7th.

Genfit Trading Down 2.0 %

Shares of Genfit stock traded down $0.07 during trading on Monday, hitting $3.40. 20,692 shares of the company were exchanged, compared to its average volume of 8,705. Genfit has a fifty-two week low of $3.35 and a fifty-two week high of $6.42. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. The firm has a 50 day moving average price of $3.73 and a 200 day moving average price of $4.40.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.